Supreme Court Ruling Clears Path for CRISPR Innovation

REDWOOD CITY, CA – April 01, 2026 – A multi-year legal battle over foundational gene-editing technology concluded today as the Supreme Court of the United States denied a petition from Agilent Technologies, Inc., finalizing the invalidation of two key CRISPR-related patents. The decision is being hailed as a landmark victory for open innovation, clearing a significant intellectual property hurdle that could accelerate the development of new genetic therapies.

The court's order leaves in place a June 2025 ruling from the U.S. Court of Appeals for the Federal Circuit, which had affirmed that all claims within Agilent's U.S. Patent Nos. 10,337,001 and 10,900,034 were unpatentable. This outcome solidifies the position of Synthego, the genome engineering company that initiated the challenge, and is expected to have wide-ranging implications for the biotechnology industry.

"We are deeply grateful for this final resolution," said Craig Christianson, CEO at Synthego, in a statement. "Our goal in pursuing this challenge was never about a single dispute, but about our commitment to the broader scientific community."

The End of a Multi-Year Legal Battle

The legal saga began when Synthego challenged the validity of Agilent's patents at the Patent Trial and Appeal Board (PTAB). The patents in question covered specific chemical modifications to guide RNAs (gRNAs), the molecules that direct CRISPR enzymes to their precise targets in the genome. These modifications, such as 2'-O-methyl and phosphonoacetate, are widely used to improve the stability and efficiency of the gene-editing process.

In May 2023, the PTAB sided with Synthego, ruling that Agilent’s claims were invalid because they were based on previously known technology. The board found that the modifications were obvious to researchers at the time, citing prior art including a 2014 scientific publication known as "Pioneer Hi-Bred." This document, an abandoned patent application, was deemed to have sufficiently disclosed the use of such chemical modifications on guide polynucleotides.

Agilent appealed the decision, arguing that the prior art was not enabling—that is, it did not provide enough information for a skilled person to replicate the work without undue experimentation. The company contended that it was their scientists who first discovered that these specific modifications would work without disrupting the critical function of the gRNA:Cas enzyme complex. Agilent's lawyers even attempted to leverage the precedent set by the Supreme Court's Amgen v. Sanofi decision, which deals with the enablement requirements for a patent's own claims.

However, the U.S. Court of Appeals for the Federal Circuit was unconvinced. In its June 2025 decision, the court affirmed the PTAB's findings, noting that substantial evidence showed the prior art did disclose chemically modified gRNAs capable of binding Cas proteins and targeting DNA. The court made a crucial distinction, clarifying that the standard for a prior-art reference to be considered enabling for anticipation purposes is different and less stringent than the standard for a patent's own claims, thereby distinguishing the case from Amgen v. Sanofi. Agilent's final recourse, a petition to the Supreme Court, was denied, bringing the matter to a definitive close.

Thinning the 'Patent Thicket' for Open Innovation

The case has been closely watched as a bellwether for the ongoing struggle over intellectual property in the burgeoning field of CRISPR technology. The term "patent thicket" is often used to describe the dense, overlapping web of patents that can stifle research and commercialization by creating legal uncertainty and high licensing costs. By challenging patents on what it argued were fundamental and widely used techniques, Synthego aimed to cut through this thicket.

"By helping to clear the patent thicket surrounding fundamental gene-editing modifications, we hope to ensure that researchers and therapeutic developers can continue to innovate without the burden of invalid patent claims," Christianson explained.

The invalidation means that the specific chemical modifications covered by Agilent's patents are now firmly in the public domain. Researchers and companies across the industry are free to use these essential techniques without fear of litigation or the need for a license from Agilent. This freedom is expected to lower barriers to entry, reduce costs for developing new tools and therapies, and foster a more collaborative and competitive research environment. The decision effectively democratizes a key component of the CRISPR toolkit, ensuring that innovation is not stalled by ownership claims on foundational knowledge.

A Strategic Victory and a Path to Cures

For Synthego, the ruling is more than a legal victory; it is a cornerstone of its corporate strategy. The company has positioned itself as a leader in providing accessible genome engineering solutions, with a growing focus on the cell and gene therapy (CGT) market. This legal clarity allows Synthego to more aggressively market its own proprietary technologies, including its novel high-fidelity nucleases like hfCas12Max and eSpOT-ON, without concerns about adjacent IP disputes over the gRNAs used with them.

The outcome reinforces Synthego's mission-driven narrative and strengthens its market position. "This result aligns perfectly with our mission to accelerate the path from discovery to cure," Christianson stated. "As we introduce our own novel nucleases and CRISPR technologies, we are inspired by the opportunity to contribute to a more open and navigable intellectual property landscape."

Ultimately, the impact of this decision may be felt most profoundly by patients. The complex and costly nature of patent litigation can create bottlenecks that slow the translation of scientific breakthroughs into life-changing medicines. By removing one such obstacle, this ruling could help accelerate the development of CRISPR-based therapies for a wide range of genetic diseases.

With the chain of appeals exhausted, the invalidation of these patents removes a significant barrier to progress. This newfound clarity in the intellectual property landscape fosters an environment where innovation in CRISPR-enabled research and therapeutics can flourish, bringing the promise of genomic medicine one step closer to reality for patients who are waiting.